BIDMC researchers confirm high toxin levels linked to more severe C. difficile infection
Written by: Jacqueline Mitchell Contact: Chloe Meck, email@example.com
OCTOBER 12, 2021
First-of-its-kind study paves the way to more predictive tests for the hard-to-eradicate infection
BOSTON – Estimated to cause almost half a million infections per year, the bacterium Clostridioides difficile, also known as C. difficile or “C. diff,” can cause diarrhea and inflammation of the large intestine. Most often affecting patients who are older and/or have weakened immune systems, C. difficile infections are especially common among hospitalized patients and in patients who have recently completed a course of antibiotics. While several tests can detect the presence of C. difficile, healthy people can harbor the bacterium without becoming ill. A quantitative relationship between C. difficile and disease severity had not been clearly established.
In a new publication appearing in the journal Clinical Infectious Diseases, researcher-physicians at Beth Israel Deaconess Medical Center (BIDMC) used a novel, highly-sensitive test to measure the amount of toxin produced by C. difficile in the stool of patients with suspected infections. The team followed the patients – who were hospitalized at BIDMC and at Texas Medical Center in Houston -- for 40 days after the onset of infection. The team found that the concentration of C. difficile toxins in the stool was linked to how sick patients were at the time of diagnosis and was also associated with adverse outcomes, including the risk of the infection returning after treatment.
“Disease-causing C. difficile strains produce toxins that directly damage the tissues of the large intestine, leading to the symptoms of C. difficile infection, including severe diarrhea, nausea and stomach pain,” said first author Carolyn D. Alonso, MD, director of the Transplant and Immunocompromised Host Program in the Division of Infectious Diseases at BIDMC and assistant professor of medicine at Harvard Medical School (HMS). “While prior studies had shown a possible association between stool toxin levels and clinical outcomes, this study was the first of its kind to convincingly demonstrate that the concentration of C. difficile toxins influences disease severity.”
“This research lays the foundation for developing a highly accurate, single-step test to better diagnose C. difficile infection and predict clinical outcomes,” said senior/corresponding author Nira R. Pollock, MD, PhD, also of the Division of Infectious Diseases at BIDMC, associate medical director of the Infectious Diseases Diagnostic Laboratory at Boston Children’s Hospital, and associate professor of pathology and medicine at HMS. “The next steps for the research will combine this ultrasensitive and quantitative stool toxin test with other biomarkers to try to create a test that can determine who really has C. difficile infection and who is most likely to have worse clinical outcomes.”
“It is well-recognized that C. difficile-associated diarrhea and colitis are caused by toxins A and B,” said co-lead author Ciarán P Kelly, MD, medical director of the Celiac Center at BIDMC and professor of medicine at HMS. “However, this study clearly shows that toxin quantities are associated with baseline disease severity as well as negative outcomes such as need for admission to the ICU and/or death. Hence, measuring toxin concentrations in stool can help physicians to predict the likely course of the illness and plan their management steps accordingly.”
Co-authors included Kaitlyn Daugherty, Christine Cuddemi, Javier Villafuerte-Gálvez, Nicole C. White, Xinhua Chen, Hua Xu, Rebecca Sprague and Caitlin Barrett of BIDMC; Kevin W. Garey and Anne J Gonzales-Luna of University of Houston College of Pharmacy; David Williams of Boston Children's Hospital; and Mark Miller, Agnès Foussadier, Aude Lantz, and Alice Banz of bioMérieux.
This study was funded by a grant from the National Institute of Allergy and Infectious Diseases (5R01AI116596-05, to N.R.P. and C.P.K.) as well as National Institute of Health Loan Repayment Funding (to C.D.A.). Simoa assays were provided as an in-kind service by bioMérieux.
Alonso has received grant support from Merck. Kelly has acted as a paid consultant to Artugen, Facile Therapeutics, Ferring, First Light Biosciences, Finch, Janssen (J&J), Matrivax, Merck, Seres, Pfizer and Vedanta. Please see the publication for a complete list of financial disclosures.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox.
Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,800 physicians and 38,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.